Autoimmune CAR-T and Immune Reset Clinical Landscape Report 2026: Trials, Readouts and White Space
Turn fragmented clinical intelligence into a decision-ready landscape. This report was assembled with PatSnap MCP Servers for Clinical Trials, Drug & Asset, and Company & Deal Intelligence. Explore the PatSnap MCP Marketplace to bring the same structured evidence into your own AI workflow.
Data snapshot: 16 July 2026. This landscape is a strategic research view, not medical advice. Trial status and timing can change; confirm records before making development or investment decisions.
Executive view
Autoimmune cell therapy is moving from academic proof-of-concept toward registrational development, while in-vivo CAR generation and relapse management could reshape cost, access, and repeatability.
How this report was built with PatSnap MCP
The workflow first used the Clinical Trials MCP to search the topic and then called clinical_trial_fetch for design details: phase, status, enrollment, sponsor, geography, primary endpoint and expected timing. It separately used clinical_trial_result_fetch to inspect indexed readouts. The Drug & Asset MCP drug_fetch call added target and global development status, while Company & Deal Intelligence organization_fetch added sponsor context. This sequence keeps trial claims traceable and prevents asset-level assumptions from being inferred from a company name alone.
Trial landscape table
| Trial | Asset / mechanism | Phase / status | Sponsor | Geography | Primary endpoint | Readout |
|---|---|---|---|---|---|---|
| NCT07629596 | Arnovie101 mRNA-LNP in-vivo CAR-T | Early Phase 1; recruiting | Sponsor not listed | China | DLT and AE/SAE incidence | Primary completion May 2027 |
| NCT07657793 | Sirolimus in SLE-associated ITP | Phase 2/3; recruiting | Chinese SLE Treatment and Research Group | China | ITP response at week 24 | Primary completion Sep 2027 |
| NCT07678203 | Dapagliflozin in lupus nephritis | Phase 1/2; active | Sponsor not listed | Mexico | KDIGO renal remission | Primary completion Jan 2027 |
| JPRN-jRCTs031260239 | 18F-FAPI imaging in CTD-ILD | Phase 2; recruiting | Sponsor not listed | Japan | DLCO and progressive fibrosis | Readout timing not listed |
The table is intentionally decision-oriented: endpoint choice, geographic reach and readout timing are displayed beside phase and sponsor. A large Phase 3 program can still have a long evidence gap, while a small Phase 2 study may answer a strategically important biomarker or tolerability question sooner.
What the indexed results say
- The Phase 2 LUMINA result record reported a 60% complete renal response at six months for obecabtagene autoleucel.
- A Phase 1 CARLYSLE record noted a reversible liver injury counted as a dose-limiting toxicity, highlighting that immune reset is not risk-free.
- A case series described relapse-management strategies after autologous CD19 CAR-T, underscoring the need for retreatment algorithms and long follow-up.
Result records should be interpreted in context. Cross-trial comparisons can be distorted by population, baseline risk, estimand, dose, follow-up and analysis set. The useful signal is not a simplistic ranking; it is how each result changes the next development question.
Build your own living clinical map: connect to PatSnap MCP Servers and combine trial design, result, asset and organization records without manually reconciling multiple databases.
Asset and sponsor context
Drug & Asset data identify obecabtagene autoleucel as a CD19-directed asset with approved status in oncology and Arnovie101 as a clinical-stage CD8-related program. The competitive question is no longer only whether B-cell depletion can induce remission; it is which manufacturing model, target depth, and safety package can make immune reset scalable.
Where the white space is
- Randomized comparisons against best available immunosuppression with organ-specific endpoints.
- Standard definitions for treatment-free remission, immune reconstitution and relapse.
- Outpatient or in-vivo delivery models that reduce lymphodepletion and manufacturing burden.
- Evidence in lupus nephritis, systemic sclerosis, myositis and neurologic autoimmunity using harmonized follow-up.
Strategic implications
For sponsors, the strongest differentiation opportunity is usually not “another asset in the same class.” It is a trial package that resolves a known decision gap: an active comparator, a better-defined responder population, a safer delivery model, a hard outcome, or a credible plan for sequencing. For business-development teams, the same landscape can identify assets whose mechanism is crowded but whose evidence architecture is differentiated. For investors, endpoint maturity and operational feasibility deserve as much attention as nominal phase.
What to monitor next
Track status changes, protocol amendments, primary-completion dates, newly indexed results, and sponsor ownership. Re-run the same MCP queries on a schedule and compare deltas rather than rebuilding the landscape from scratch. Pay special attention when an endpoint moves from a surrogate to a clinical outcome, when a single-country program becomes multinational, or when an emerging sponsor adds a large pharmaceutical collaborator.
Bottom line
Autoimmune CAR-T and Immune Reset is a fast-moving clinical field with meaningful competition and equally meaningful evidence gaps. A useful landscape must connect design, results, mechanism and sponsor—not list trials in isolation.
Ready to reproduce this analysis? Explore PatSnap MCP Servers and use Clinical Trials, Drug & Asset, and Company & Deal Intelligence as structured building blocks for research, monitoring and SEO-ready clinical reports.
